当前位置:
首页
网刊
急性ST段抬高型心肌梗死的规范化溶栓治疗和溶栓剂选择
急性ST段抬高型心肌梗死的规范化溶栓治疗和溶栓剂选择
吴丹勇1,李景悦2

1 天士力控股集团,天津 300410;2 天津天士力医药商业有限公司,天津 300410
Standardized thrombolytic therapy and thrombolytic agent selection for acute ST segment elevation myocardial infarction
(Tasly Holding Group Co.,Ltd.,Tianjin 300410,China;2 Tianjin Tasly Pharmaceutical Commercial Ltd., Tianjin 300410,China)

摘要参考文献相关文章

起始页:1528

摘要:[摘要] 急性心肌梗死是致死率最高的心血管疾病之一,及时优化再灌注治疗以及第一时间开通血管,可以最大限度的挽救心肌。静脉溶栓治疗是重要的再灌注治疗策略,而静脉溶栓的成功率以及安全性与溶栓剂的选择密切相关。近年研发的特异性溶栓剂的广泛使用,可以提升救治效率,令患者获益最大化。本文就不同溶栓剂的临床价值以及目前的研究进展进行综述。

关键词:[关键词] 急性心肌梗死;溶栓;溶栓剂

通讯作者:

基金项目:

作者简介:

Abstract:[Abstract] Acute myocardial infarction is one of the most deadly cardiovascular diseases. Early reperfusion can restore the blood flow at the first time, and maximize the rescue of the ischemic myocardium. Intravenous thrombolysis is a significant reperfusion method. Efficacy and safety of thrombolysis are closely related to the selection of thrombolytic agents. The wide use of new specific thrombolytic agents developed in recent years can improve the efficacy of treatment and maximize the benefit of patients. In this article, the clinical values of different thrombolytic agents and the current research progress were reviewed.

Key words:[Key words] acute myocardial infarction; thrombolysis; thrombolytic agents

    [1] 陈伟伟,高润霖,刘力生,等. 《中国心血管病报告2015》概要[J]. 中国循环杂志, 2016, 31(6): 624-632.
    [2] LI J, LI X, WANG Q, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-retrospective acute myocardial infarction study): a retrospective analysis of hospital data[J]. Lancet,2015,385(9966):441-451.
    [3] 中华医学会心血管病学分会. 急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-393.
    [4] 国家卫生计生委合理用药专家委员会,中国药师协会. 急性ST段抬高型心肌梗死溶栓治疗的合理用药指南[J].中国医学前沿杂志(电子版),2016,8(8):17-33.
    [5] WILLIAM R, BELL JR. Evaluation of thrombolytic agents[J].Drug, 1997, 54(Suppl 3): 11.
    [6] SMALLING RW. A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to clinical outcome[J]. Am J Health-syst Pharm, 1997, 54(Suppl 1): S17-S22.
    [7] 中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会. 瑞替普酶在ST段抬高心肌梗死溶栓治疗的中国专家共识[J]. 中国医药导刊,2012,14(6):921-925.
    [8] 宁荣霞,王瑞,崔晓迎. 新型溶栓药物重组人尿激酶原[J]. 中国新药杂志,2008,17(5):430-432
    [9] 梁峰, 胡大一, 吴明营, 等. 重组尿激酶原治疗急性心肌梗死的疗效和安全性评价[J]. 中国实用内科杂志, 2005, 26(3):187-189.
    [10] 许骥, 华琦, 刘力松, 等. 重组人尿激酶原与尿激酶对急性心肌梗死患者纤溶系统影响的比较[J]. 首都医科大学学报,2005, 26(2):132-135.
    [11] 肖成祖. 溶栓新药尿激酶原治疗急性心肌梗死的研究进展和探讨[J]. 医学研究杂志, 2011,40(1):5-8.
    [12] 傅晓霞,肖文剑,杨帆,等.血栓通注射液对急性心肌梗死BNP水平影响研究

    [J].今日药学,2014,24(4):57-59.